Screening Libraries
Cat. | Size | Price | Stock | |
P20284 | 1mg/well * 9 Compounds | Inquiry | In stock | Contact Us |
P20284 | 100uL/well (10mM solution) * 9 Compounds | Inquiry | In stock |
manager@chemfaces.com | |
Tel | (0086)-27-8423-7683 |
Shelf Life | (0086)-27-84254680 |
Manufacturer | Wuhan ChemFaces Biochemical Co., Ltd. |
Container | 96 Well Format Sample |
Storage | Protected from air and light, refrigerate or freeze(2-8 °) |
Shelf Life | 24 months (2-8 °) |
Intended Use | For research use only. Not for human use. Not sell to patients |
1. The products in the ChemFaces screening libraries are all from plants. |
2. The biological activities or pharmacological activities of all the ChemFaces products are derived from the databases of all over the world the latest literatures, you can according to the product manuals on our website to access the relevant literatures, hope that our informations can give some inspirations and help to your research. |
3.The collections of unique natural products, which include antioxidants, anti-inflammatory, antibacterial, anticancer, and ect. Can be used for high throughput screening (HTS) and high content screening (HCS), is to help you carry out new drug screening, the emergence of new indications and other professional tools. |
4.Structurally diverse, medicinally active, and cell permeable, NMR and HPLC validated to ensure high purity. |
5. ChemFaces offers customized bioactive screening libraries , whereby you choose the specific compounds you want in the library, the quantities, plate map, concentration, and format (dry/solid or DMSO solution). |
Catalog No. | Information |
CFN99916 | Beta-Sitosterol Beta-Sitosterol is a novel plant-derived angiogenic factor which may have potential pharmaceutical applications for the management of chronic wounds. It has potent anti-inflammatory, anti-proliferation, and pro- apoptosis activities, it also possesses antipyretic activity, similar to acetylsalicylic acid. |
CFN99506 | Aristolochic acid B Aristolochic acid II (Aristolochic acid B,AAII), one of the major components of the carcinogenic plant extract aristolochic acid, is known to be mutagenic and to form DNA adducts in vitro and in vivo, AAII shows more carcinogenic risk than aristolochic acid I, and this may be, at least partly, the result of its increased levels in kidney and plasma. |
CFN99505 | Aristolochic acid A Aristolochic acid A is a potent nephrotoxin, which strongly induced toxic damage during ovarian maturation by inhibiting Akt phosphorylation-mediated suppression of apoptosis. |
CFN98071 | Magnoflorine Magnoflorine possesses high activity as α-glucosidase inhibitor in vitro and in vivo, has antidiabetic potential activity; it also has sedative and anxiolytic effects, probably mediated by a GABAergic mechanism of action. Magnoflorine has protective effects, mediated by some mechanism other than prevention of micelle formation or protection of the erythrocyte membrane against osmotic imbalance. |
CFN97557 | Allantoin Allantoin, as I-1R agonist, has the potential to develop as a new therapeutic agent for hypertension. Allantoin has memory-enhancing, anti-oxidative and anti-inflammatory activities; it can enhance the antifungal activity of Nanoencapsulation. Allantoin is a skin conditioning agent that promotes healthy skin, stimulates new and healthy tissue growth. Allantoin mediates PI3K-Akt-GSK-3β signal pathway. |
CFN99222 | Aristolactam FI Aristolactam FI shows platelet aggregation inhibitory activity.It is a potential cancer chemotherapeutic and chemopreventive agent. |
CFN98904 | Aristolactam BIII Aristolactam BIII possesses anti-platelet aggregation activity in vitro, it also shows significant cytotoxic activity (IC50 values < 4 microg/mL) against P-388, HT-29 and A549 cell lines in vitro. |
CFN98903 | Aristolactam BII Aristolactam BII exhibits antimicrobial and antiinflammatory activity, it shows significant activity towards DPPH radical scavenging and potent inhibitory effects against tyrosinase mushroom. Aristolactam BII also exerts its significant neuroprotective effects on glutamate-injured primary cultures of rat cortical cells by directly inhibiting the production of nitric oxide. |
CFN97551 | Aristolactam AIIIa Aristolactam AIIIa is a new type of Plk1 inhibitors, targeting the Polo Box domain (PBD), it has anti-tumor activity. Aristolactam IIIa shows inhibition of platelet aggregation induced by collagen or arachidonic acid. |